199 related articles for article (PubMed ID: 24692500)
1. Exploring the recent trend in esophageal adenocarcinoma incidence and mortality using comparative simulation modeling.
Kong CY; Kroep S; Curtius K; Hazelton WD; Jeon J; Meza R; Heberle CR; Miller MC; Choi SE; Lansdorp-Vogelaar I; van Ballegooijen M; Feuer EJ; Inadomi JM; Hur C; Luebeck EG
Cancer Epidemiol Biomarkers Prev; 2014 Jun; 23(6):997-1006. PubMed ID: 24692500
[TBL] [Abstract][Full Text] [Related]
2. Trends in esophageal adenocarcinoma incidence and mortality.
Hur C; Miller M; Kong CY; Dowling EC; Nattinger KJ; Dunn M; Feuer EJ
Cancer; 2013 Mar; 119(6):1149-58. PubMed ID: 23303625
[TBL] [Abstract][Full Text] [Related]
3. The impact of obesity on the rise in esophageal adenocarcinoma incidence: estimates from a disease simulation model.
Kong CY; Nattinger KJ; Hayeck TJ; Omer ZB; Wang YC; Spechler SJ; McMahon PM; Gazelle GS; Hur C
Cancer Epidemiol Biomarkers Prev; 2011 Nov; 20(11):2450-6. PubMed ID: 21930957
[TBL] [Abstract][Full Text] [Related]
4. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends.
Thrift AP; Whiteman DC
Ann Oncol; 2012 Dec; 23(12):3155-3162. PubMed ID: 22847812
[TBL] [Abstract][Full Text] [Related]
5. Development, calibration, and validation of a U.S. white male population-based simulation model of esophageal adenocarcinoma.
Hur C; Hayeck TJ; Yeh JM; Richards EM; Spechler SJ; Gazelle GS; Kong CY
PLoS One; 2010 Mar; 5(3):e9483. PubMed ID: 20208996
[TBL] [Abstract][Full Text] [Related]
6. Comparing trends in esophageal adenocarcinoma incidence and lifestyle factors between the United States, Spain, and the Netherlands.
Kroep S; Lansdorp-Vogelaar I; Rubenstein JH; Lemmens VE; van Heijningen EB; Aragonés N; van Ballegooijen M; Inadomi JM
Am J Gastroenterol; 2014 Mar; 109(3):336-43; quiz 335, 344. PubMed ID: 24343546
[TBL] [Abstract][Full Text] [Related]
7. Incidence of Esophageal Adenocarcinoma and Causes of Mortality After Radiofrequency Ablation of Barrett's Esophagus.
Wolf WA; Pasricha S; Cotton C; Li N; Triadafilopoulos G; Muthusamy VR; Chmielewski GW; Corbett FS; Camara DS; Lightdale CJ; Wolfsen H; Chang KJ; Overholt BF; Pruitt RE; Ertan A; Komanduri S; Infantolino A; Rothstein RI; Shaheen NJ
Gastroenterology; 2015 Dec; 149(7):1752-1761.e1. PubMed ID: 26327132
[TBL] [Abstract][Full Text] [Related]
8. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis.
Sikkema M; de Jonge PJ; Steyerberg EW; Kuipers EJ
Clin Gastroenterol Hepatol; 2010 Mar; 8(3):235-44; quiz e32. PubMed ID: 19850156
[TBL] [Abstract][Full Text] [Related]
9. Dating the rise of esophageal adenocarcinoma: analysis of Connecticut Tumor Registry data, 1940-2007.
Abrams JA; Sharaiha RZ; Gonsalves L; Lightdale CJ; Neugut AI
Cancer Epidemiol Biomarkers Prev; 2011 Jan; 20(1):183-6. PubMed ID: 21127287
[TBL] [Abstract][Full Text] [Related]
10. An Accurate Cancer Incidence in Barrett's Esophagus: A Best Estimate Using Published Data and Modeling.
Kroep S; Lansdorp-Vogelaar I; Rubenstein JH; de Koning HJ; Meester R; Inadomi JM; van Ballegooijen M
Gastroenterology; 2015 Sep; 149(3):577-85.e4; quiz e14-5. PubMed ID: 25935635
[TBL] [Abstract][Full Text] [Related]
11. The prevalence of Barrett's esophagus in the US: estimates from a simulation model confirmed by SEER data.
Hayeck TJ; Kong CY; Spechler SJ; Gazelle GS; Hur C
Dis Esophagus; 2010 Aug; 23(6):451-7. PubMed ID: 20353441
[TBL] [Abstract][Full Text] [Related]
12. The Impact of Uncertainty in Barrett's Esophagus Progression Rates on Hypothetical Screening and Treatment Decisions.
Kroep S; Lansdorp-Vogelaar I; van der Steen A; Inadomi JM; van Ballegooijen M
Med Decis Making; 2015 Aug; 35(6):726-33. PubMed ID: 25277672
[TBL] [Abstract][Full Text] [Related]
13. The Role of Gastroesophageal Reflux and Other Factors during Progression to Esophageal Adenocarcinoma.
Hazelton WD; Curtius K; Inadomi JM; Vaughan TL; Meza R; Rubenstein JH; Hur C; Luebeck EG
Cancer Epidemiol Biomarkers Prev; 2015 Jul; 24(7):1012-23. PubMed ID: 25931440
[TBL] [Abstract][Full Text] [Related]
14. Predicting the Future Burden of Esophageal Cancer by Histological Subtype: International Trends in Incidence up to 2030.
Arnold M; Laversanne M; Brown LM; Devesa SS; Bray F
Am J Gastroenterol; 2017 Aug; 112(8):1247-1255. PubMed ID: 28585555
[TBL] [Abstract][Full Text] [Related]
15. Esophageal cancer in Canada: trends according to morphology and anatomical location.
Otterstatter MC; Brierley JD; De P; Ellison LF; Macintyre M; Marrett LD; Semenciw R; Weir HK
Can J Gastroenterol; 2012 Oct; 26(10):723-7. PubMed ID: 23061066
[TBL] [Abstract][Full Text] [Related]
16. Subjects with prostate cancer are less likely to develop esophageal cancer: analysis of SEER 9 registries database.
Cooper SC; Trudgill NJ
Cancer Causes Control; 2012 Jun; 23(6):819-25. PubMed ID: 24251326
[TBL] [Abstract][Full Text] [Related]
17. Magnitude and Time-Trends of Post-Endoscopy Esophageal Adenocarcinoma and Post-Endoscopy Esophageal Neoplasia in a Population-Based Cohort Study: The Nordic Barrett's Esophagus Study.
Wani S; Holmberg D; Santoni G; Kauppila JH; Farkkila M; von Euler-Chelpin M; Shaheen NJ; Lagergren J
Gastroenterology; 2023 Oct; 165(4):909-919.e13. PubMed ID: 37279832
[TBL] [Abstract][Full Text] [Related]
18. The Annual Risk of Esophageal Adenocarcinoma Does Not Decrease Over Time in Patients With Barrett's Esophagus.
Nguyen T; Thrift AP; Yu X; Duan Z; El-Serag HB
Am J Gastroenterol; 2017 Jul; 112(7):1049-1055. PubMed ID: 28244499
[TBL] [Abstract][Full Text] [Related]
19. Time trends in the incidence of esophageal adenocarcinoma, gastric adenocarcinoma, and superficial esophagogastric junction adenocarcinoma.
Matsuno K; Ishihara R; Ohmori M; Iwagami H; Shichijyo S; Maekawa A; Kanesaka T; Yamamoto S; Takeuchi Y; Higashino K; Uedo N; Matsunaga T; Morishima T; Miyashiro I
J Gastroenterol; 2019 Sep; 54(9):784-791. PubMed ID: 30927083
[TBL] [Abstract][Full Text] [Related]
20. Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia.
Parasa S; Vennalaganti S; Gaddam S; Vennalaganti P; Young P; Gupta N; Thota P; Cash B; Mathur S; Sampliner R; Moawad F; Lieberman D; Bansal A; Kennedy KF; Vargo J; Falk G; Spaander M; Bruno M; Sharma P
Gastroenterology; 2018 Apr; 154(5):1282-1289.e2. PubMed ID: 29273452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
